Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.

ABSTRACT:

Objective

To assess if 12 novel circulating biomarkers, when added to 'standard predictors' available in general practice, could improve the 10-year prediction of cardiovascular events and mortality in patients with stable coronary heart disease.

Design

The patients participated as placebo receiving patients in the randomised clarithromycin for patients with stable coronary artery disease (CLARICOR) trial at a random time in their disease trajectory.

Setting

Five Copenhagen University cardiology departments and a coordinating centre.

Participants

1998 participants with stable coronary artery disease.

Outcomes

Death and composite of myocardial infarction, unstable angina pectoris, cerebrovascular disease and death.

Results

When only 'standard predi

SUBMITTER: Winkel P 

PROVIDER: S-EPMC7443269 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature